Alice Indini retweeted
Great job, #Iampractisingoncologist! We r the @esmo_eur_oncology commitee involved in feeling the gap between research and daily clinical practice. If you have a full 8-hours clinic and look4a way to be updated on what’s going on in the oncology field, welcome on board!
Alice Indini retweeted
Alexios Matikas, OncologyPRO Working Group Member & ESMO #YoungOncologist Committee Member, on why OncologyPRO is an essential tool to help oncologists in their #dailypractice, thanks to its accessibility, ease of use, and content depth.
ow.ly/pmwU50M9esW
#oncology
Alice Indini retweeted
Great job from the Practising Oncologist Working Group! Very useful!!!!
Recently updated 📢 All 15 ESMO Checklists: hands-on self-assessment tools to help you check essential steps recommended in ESMO Guidelines have been taken in your daily practice
ow.ly/5Uu750L3312
@brasiuniene @DrMeredithGT @LazarPo31787807 @BennounaJaafar @G_LipositsMD
Alice Indini retweeted
Calling all practising oncologists 📢 Take the ESMO Practising Oncologists Working Group survey so we can better understand your practice needs & opinions on current products. ow.ly/FS3650KMUi7
@brasiuniene @DrMeredithGT @LazarPo31787807 @BennounaJaafar @G_LipositsMD
Alice Indini retweeted
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges. pubmed.ncbi.nlm.nih.gov/3575…
Alice Indini retweeted
Our study on #mucosal #melanoma is now online in @Annals_Oncology - Although retrospective, this study represents the largest report to date analyzing the efficacy of ICIs in this rare cancer that carries a poor prognosis. Here are some key points:
Mucosal melanoma, representing 2% of melanomas, has a distinct biology & carries a poor prognosis.
In this cohort of 545 patients published in Annals of Oncology, @FDimitriouMD @ProfGLongMIA and coll. studied the efficacy of immune checkpoint inhibitors
annalsofoncology.org/article…
Alice Indini retweeted
Soft Tissue #Sarcomas Webinar ⏰ 29/3, 18:30 CEST Registration open for this live discussion of a real-world case. Live viewers: certificate of attendance & 1 ESMO-MORA point
Full info 🔗 ow.ly/YIT950ImoNY
@AliceIndini @SilviaStacchia @pawel_sobczuk @jeanyvesblay #scmsm
Alice Indini retweeted
#ESMOPreceptorship on Molecular #CancerBiology for Practising Oncologists & #Cancer Treatment De-escalation 2022: Multidisciplinary management, standards of care & future perspectives
ow.ly/pgJv50HQFsZ
@BennounaJaafar @brasiuniene @PietDirix @G_LipositsMD @LazarPo31787807
Alice Indini retweeted
Just published! We proudly present "Hallmarks of Cancer: New Dimensions" by Douglas Hanahan, the third update to the seminal series. bit.ly/3GkSqZK @Ludwig_Cancer
Alice Indini retweeted
On behalf of my colleagues, so excited to bring a new and safer immune checkpoint inhibitor combination to our patients with advanced melanoma, Relatlimab (anti-LAG3) with nivolumab improves PFS, minor increase in toxicity, new frontiers for #Immunotherapy nejm.org/doi/full/10.1056/NE…
Alice Indini retweeted
👉 Check out the @myESMO Practicing Oncologists Working Group's new series of Spotlight presentations featuring highlights from #ESMO21
oncologypro.esmo.org/meeting…
Alice Indini retweeted
Mucosal melanomas: molecular profile and therapy. What physicians need to know!!
Alice Indini retweeted
New #JITC article: Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties bit.ly/3pW3yFk @SripadRam
